Certolizumab

• Rheumatoid Arthritis
• Psoriatic Arthritis
• Ankylosing Spondylitis
• Crohn's Disease

Certolizumab pegol is a PEGylated tumor necrosis factor alpha (TNF-α) inhibitor used to treat various inflammatory autoimmune conditions. This biologic medication has a unique structure lacking an Fc region, which may provide certain advantages including reduced placental transfer during pregnancy.

Mechanism of Action

Certolizumab pegol consists of a humanized antibody Fab' fragment specific for TNF-α that is conjugated to polyethylene glycol (PEG). Unlike other TNF inhibitors, it lacks the Fc portion of a complete antibody. The Fab' fragment binds to and neutralizes human TNF-α, preventing it from binding to TNF receptors on cell surfaces. This blocks TNF-α's pro-inflammatory effects, including activation of immune cells, induction of cytokines, and promotion of joint destruction. The PEGylation extends the half-life, allowing less frequent dosing. The absence of the Fc region means certolizumab does not induce complement-mediated cytotoxicity or antibody-dependent cell-mediated cytotoxicity.

Available Formulations

Certolizumab pegol is available as a solution for subcutaneous injection in prefilled syringes (200 mg/mL) and as a lyophilized powder requiring reconstitution. The prefilled syringes are designed for self-administration after proper training. The medication requires refrigeration but should be brought to room temperature before injection.

Medical Uses

Certolizumab is FDA-approved for moderately to severely active rheumatoid arthritis (RA), active psoriatic arthritis (PsA), active ankylosing spondylitis (AS), moderate to severe plaque psoriasis, active non-radiographic axial spondyloarthritis with objective signs of inflammation, and moderately to severely active Crohn's disease (when conventional therapy has failed). It can be used alone or in combination with non-biologic DMARDs such as methotrexate.

Dosing Guidelines

For rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and axial spondyloarthritis, the recommended dose is 400 mg (two 200 mg injections) initially and at weeks 2 and 4, followed by 200 mg every other week or 400 mg every 4 weeks for maintenance. For plaque psoriasis, the loading dose is the same, with maintenance of 400 mg every other week. For Crohn's disease, the loading dose is followed by 400 mg every 4 weeks. If response is incomplete, consider maintenance of 400 mg every 4 weeks.

Important Safety Information

Certolizumab carries a boxed warning for serious infections (including tuberculosis, invasive fungal infections, and bacterial/viral infections) and malignancy (including lymphoma and other malignancies, some in children and adolescents). All patients should be tested for latent tuberculosis before starting therapy. The medication should not be initiated during active infections. Other serious risks include hepatitis B reactivation, heart failure worsening, demyelinating disease, hematologic reactions, and hypersensitivity reactions including anaphylaxis.

Drug Interactions

Certolizumab should not be used concurrently with other biologic DMARDs or TNF blockers (anakinra, abatacept, rituximab) due to increased infection risk. Live vaccines should be avoided during treatment. There are no significant pharmacokinetic interactions with methotrexate or other non-biologic DMARDs. Therapeutic drug monitoring may be considered in patients with inadequate response or suspected immunogenicity.

Where Certolizumab Sits Among the Biologics

Certolizumab is rarely the first drug tried for any of its indications. In rheumatoid arthritis, conventional therapy with methotrexate comes first, and a TNF inhibitor is added when disease activity remains moderate to high after an adequate trial. Among the TNF inhibitors, adalimumab and etanercept are more commonly chosen at that point simply because they have the longest use and the broadest formulary coverage, and head-to-head efficacy differences across the class are small.

Two features make certolizumab the deliberate choice rather than the default. The first is pregnancy: because the molecule lacks an Fc region, it does not cross the placenta in the third trimester the way intact antibodies do, and it is the TNF inhibitor most often continued through pregnancy when disease activity requires ongoing suppression. The second is response after failure of another agent in the class; switching within the TNF inhibitors still works for a meaningful proportion of patients, particularly when the first drug lost effect over time rather than never working. In Crohn's disease, certolizumab is one option among several biologic classes, and gastroenterology usually leads that choice. The MedlinePlus certolizumab monograph gives the patient-level summary.

Screening, Timing, and the First Few Months

Before the first injection, latent tuberculosis testing and hepatitis B serology are completed and reviewed, not merely ordered, and vaccinations are brought current because live vaccines cannot be given once treatment starts. Shingles and pneumococcal protection are worth arranging in advance rather than afterward. The National Institute of Arthritis and Musculoskeletal and Skin Diseases explains the reasoning behind this screening for patients.

Response is assessed over months, not weeks. The loading doses front-load exposure, and most patients who will respond show measurable improvement in joint counts and inflammatory markers within the first three months; continuing unchanged past six months without response is uncommon. Injection-site reactions are frequent early and usually settle. Two practical rules prevent most trouble: doses are held during an active infection and resumed once it has resolved, and any fever, persistent cough, or unexplained weight loss is reported rather than waited out. Our immunology team coordinates the screening, the vaccine timing, and the hold-and-restart decisions with the prescribing rheumatologist.

Special Populations

Unlike other TNF inhibitors, certolizumab has minimal to no placental transfer due to the absence of the Fc region. It is the only TNF inhibitor with pregnancy data suggesting no increased risk of birth defects and is often preferred if TNF inhibition is needed during pregnancy. Small amounts are present in breast milk; the benefits of breastfeeding should be considered. Safety and efficacy have not been established in pediatric patients. No dose adjustment is needed for elderly patients or those with renal impairment. Patients with hepatic impairment have not been specifically studied.